Experimental group:Tislelizumab combined with recombinant human adenovirus type 5

2 trials

Sponsors

Nanjing Drum Tower Hospital, Shanxi Provincial Cancer Hospital

Conditions

non-small cell lung cancer

Early Phase 1

Tislelizumab combined with recombinant human adenovirus type 5 injection in patients with advanced NSCLC who failed prior immunotherapy: an exploratory single-arm study

RecruitingChiCTR2100054954

Nanjing Drum Tower Hospitalnon-small cell lung cancer

Start: 2021-12-29Updated: 2023-01-09

Tislelizumab combined with recombinant human adenovirus type 5 injection in PD-(L) 1-resistant patients with advanced non-squamous NSCLC

RecruitingChiCTR2300072094

Shanxi Provincial Cancer Hospitalnon-small cell lung cancer

Start: 2023-06-01Updated: 2023-06-12